Showing results (251-260 of 322) with videos related to
Sort By:
Pageof 33
Nature|June 5, 2020
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin KMikołaj Słabicki, Zuzanna Kozicka, Georg Petzold, et al.Blood|June 17, 2022
TET2-mutant clonal hematopoiesis and risk of goutMridul Agrawal, Abhishek Niroula, Pierre Cunin, et al.Science Translational Medicine|February 10, 2017
Drug discovery for Diamond-Blackfan anemia using reprogrammed hematopoietic progenitorsSergei Doulatov, Linda T Vo, Elizabeth R Macari, et al.Blood|January 29, 2021
Modeling and targeting of erythroleukemia by hematopoietic genome editingIlaria Iacobucci, Chunxu Qu, Elena Varotto, et al.Blood|May 8, 2026
Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapiesLucia Y Chen, Adolfo Aleman, Marta Larrayoz, et al.Biorxiv : the Preprint Server for Biology|October 24, 2023
Circulating senescent myeloid cells drive blood brain barrier breakdown and neurodegenerationC Matthias Wilk, Flurin Cathomas, Orsolya Török, et al.Nature|January 15, 2025
Prolonged persistence of mutagenic DNA lesions in somatic cellsMichael Spencer Chapman, Emily Mitchell, Kenichi Yoshida, et al.Cancer Cell|August 15, 2018
Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene MutationsStanley Chun-Wei Lee, Khrystyna North, Eunhee Kim, et al.Blood Advances|November 19, 2019
Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysisKathy L McGraw, Chia-Ho Cheng, Y Ann Chen, et al.Blood|December 14, 2023
Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AMLWallace Bourgeois, Jevon A Cutler, Brandon J Aubrey, et al.Pageof 33